Shanghai Yingrui Biopharma Co.,Ltd.
Home
About Us
ABOUT US
Corporate Culture
Products
APIs & Intermediates
PEG Derivatives
The others
Services
News
Company News
Industry Trends
Contact Us
NEWS CENTER
Domestic innovative drugs have ushered in another "blockbuster drug"
In the field of biomedicine, major products with annual sales exceeding US$1 billion are vividly referred to as "blockbuster" drugs. It is reported that China has welcomed another blockbuster drug, namely Carvykti (Cediranib Injection), a CAR-T product from the Chinese innovative drug company Legend Biologics.
2026-02-06
2026
02-06
Antitumor drugs remain the focus of new drug approvals
In 2025, China's innovative drug sector delivered an impressive performance, with the National Medical Products Administration approving 76 innovative drugs for marketing throughout the year.
2026-01-20
01-20
The intelligent development of the pharmaceutical industry is accelerating once again!
Recently, eight departments including the Ministry of Industry and Information Technology
2026-01-08
01-08
The field of TGCT has ushered in a new era of targeted therapy
Tendon sheath giant cell tumor (TGCT) is a locally invasive disease that can seriously affect the quality of life of patients, causing joint pain, stiffness, swelling, and limited mobility. The working age population is a high-risk group. If left untreated or recurrent, it may lead to irreversible damage to bones, joints, and surrounding tissues. Patients have a huge and unmet clinical need for well tolerated and effective systemic treatment options. Recently, there has been good news in this dr
2025-12-24
2025
12-24
Sinovac and Innovent's blockbuster ophthalmic innovative drugs usher in new progress
Retinal vascular hyperplasia has gradually become one of the important causes of irreversible blindness in adults worldwide. Among them, age-related macular degeneration (nAMD), diabetes macular edema (DME) and other retinal neovascular diseases are particularly harmful.
2025-12-10
12-10
Another domestic new drug has obtained special exemption qualification from the US FDA
Recently, the US FDA officially granted NouvNeu004 Injection, a subsidiary of Ruijian Yilian Pharmaceutical Technology Co., Ltd., special exemption status and further approved the international phase I clinical trial of NouvNeu004 Injection for multiple system atrophy. It is reported that this is a further significant international progress made by NouvNeu004 injection after the National Medical Products Administration (NMPA) of China officially approved the Phase I-III full cycle clinical trial
2025-11-28
11-28
The 93rd API China opened in Chongqing
On November 12, 2025, the highly anticipated 93rd China International Pharmaceutical Raw Materials/Intermediates/Packaging/Equipment Fair (API China) kicked off at the Chongqing International Expo Center.
2025-11-12
11-12
Shanghai has approved 8 innovative drugs of Class 1 this year
In recent years, Shanghai has continuously promoted the development of innovative drugs and ushered in a shining moment. As of 2025, a total of 8 domestically produced Class 1 innovative drugs in Shanghai have been approved for market by the National Medical Products Administration.
2025-11-01
11-01
Another wave of innovation in China's pharmaceutical industry is sweeping the nation.
With the continuous development of innovative drugs in China, it has become a trend for innovative drugs to go global. Entering October 2025, innovative drug BD transactions remain hot, with several pharmaceutical companies announcing heavyweight BD transactions on October 16th.
2025-10-20
10-20
The tide of mergers and acquisitions among global pharmaceutical companies is rising
Recently, there have been frequent mergers and acquisitions in the global pharmaceutical industry, with pharmaceutical leaders such as Bristol Myers Squibb (BMS), Novo Nordisk, and Abbott taking action one after another. Industry insiders point out that this is not an accidental capital impulse, but a strategic necessity for global pharmaceutical companies under multiple pressures such as patent cliffs and intensified market competition. Behind every merger and acquisition, there is an important
2025-10-10
10-10